|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for NAALADL1 |
 Gene summary |
| Basic gene Info. | Gene symbol | NAALADL1 |
| Gene name | N-acetylated alpha-linked acidic dipeptidase-like 1 | |
| Synonyms | I100|NAALADASEL | |
| Cytomap | UCSC genome browser: 11q12 | |
| Type of gene | protein-coding | |
| RefGenes | NM_005468.2, | |
| Description | 100 kDa ileum brush border membrane proteinN-acetylated-alpha-linked acidic dipeptidase-like proteinNAALADase Lileal dipeptidylpeptidaseileal peptidase I100 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 602640 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000168060 | ||
| HPRD : 07212 | ||
| Vega : OTTHUMG00000165595 | ||
| Protein | UniProt: Q9UQQ1 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_NAALADL1 | |
| BioGPS: 10004 | ||
| Pathway | NCI Pathway Interaction Database: NAALADL1 | |
| KEGG: NAALADL1 | ||
| REACTOME: NAALADL1 | ||
| Pathway Commons: NAALADL1 | ||
| Context | iHOP: NAALADL1 | |
| ligand binding site mutation search in PubMed: NAALADL1 | ||
| UCL Cancer Institute: NAALADL1 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for NAALADL1 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | Y677 | R676H | STAD | 1 | H545 | A547S | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for NAALADL1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | Y677 | R676H | -1.5208785 | H545 | A547S | -0.73976182 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for NAALADL1 from PDB |
| Top |
| Differential gene expression and gene-gene network for NAALADL1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for NAALADL1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for NAALADL1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of NAALADL1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 4twe | A | H545 | ZN | ZINC(2+) | 4twe | B | H545 | CA | CALCIUM(2+) | 4twe | A | Y677 | CA | CALCIUM(2+) | 4twe | B | Y677 |
| Top |
| Conservation information for LBS of NAALADL1 |
| Multiple alignments for Q9UQQ1 in multiple species |
| LBS | AA sequence | # species | Species | D378 | VHGAVDPSSGT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D445 | AYINVDISVFA | 1 | Homo sapiens | D445 | AYINVDISVFS | 1 | Mus musculus | D445 | TYINVDISVFS | 1 | Rattus norvegicus | E417 | SWGAEEFGLIG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E425 | LIGSTEFTEEF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E428 | STEFTEEFLSK | 2 | Mus musculus, Rattus norvegicus | E428 | STEFTEEFFNK | 1 | Homo sapiens | H368 | VIYGNHRDSWV | 2 | Mus musculus, Rattus norvegicus | H368 | VLYGNHRDSWV | 1 | Homo sapiens | H545 | IYPTYHTAFDT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L261 | PLTPYLPAVPS | 1 | Homo sapiens | L261 | PLTPYLPAHPS | 1 | Mus musculus | L261 | PLTPYLPAHPV | 1 | Rattus norvegicus | T258 | FGDPLTPYLPA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y677 | FPEERYYSHVL | 2 | Homo sapiens, Rattus norvegicus | Y677 | FPEERHYSHVL | 1 | Mus musculus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |